Active ingredient of Spiriva is 22.5 μg of Tiotropium bromide monohydrate, equivalent to 18 μg of Tiotropium.
Tiotropium is a long-acting antimuscarinic drug, often called anticholinergic in clinical practice.
Spiriva significantly reduces shortness of breath throughout the treatment period, which, in turn, significantly improves the limited tolerability of the symptoms of exercise tolerance. Also, the medication significantly reduces the number of exacerbations of COPD and prolongs the time to the first exacerbation.
Spiriva significantly improves the quality of life. This improvement is observed throughout the treatment period. It was proved that Spiriva significantly reduces the number of hospitalizations associated with exacerbation of COPD, and increases the time until the first hospitalization.
Supportive bronchodilator therapy to relieve symptoms of COPD.
The drug is intended for inhalation use only.
The recommended dose of Spiriva consists of inhaling the contents of 1 capsule 1 time per day with the help of inhalation device HandiHaler. Inhalation should be done at the same time of day.
The recommended dose should not be exceeded. Capsules are not intended for oral use, capsules of the drug Spiriva can not be ingested.
Elderly patients should only use Spiriva at the recommended dose.
Spiriva is a bronchodilator, which is prescribed once a day for maintenance therapy, and which is not intended for the initial treatment of acute attacks of bronchospasm.
Like other anticholinergic drugs, Spiriva should be used with caution in patients with occlusive glaucoma, prostatic hyperplasia, or bladder neck obstruction.
Patients should avoid getting powder in the eyes. This can lead to a worsening of angle-closure glaucoma, pain or discomfort in the eyes, temporary blurred vision, a sensation of a halo or color spots in the eyes, combined with redness of the eye in the form of conjunctival hyperemia or cornea.
Spiriva should not be used more than 1 time per day.
Use During Pregnancy And Lactation. Pregnancy
Data on the use of Tiotropium in pregnant women are very limited. Pre-clinical studies have not shown any direct or indirect adverse effects on reproductive toxicity at clinically significant doses. As a precaution, Spiriva should be avoided during pregnancy.